Evelo Biosciences
About Evelo Biosciences
The gut is a central organ of the immune system which controls immunity and inflammation through its interactions with microbes in the small intestine
We are developing a new class of oral biologic therapies that engage immune cells in the small intestine to transmit effects throughout the body
Modulation of this “gut-body network" has therapeutic potential in many major diseases
For general inquiries contact: info@evelobio.com
For media inquiries contact: media@evelobio.com
For investor inquiries contact: ir@evelobio.com
NASDAQ EVLO
115 articles with Evelo Biosciences
-
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
3/16/2023
Evelo Biosciences, Inc. today reported financial results and business highlights for the fourth quarter and full year 2022.
-
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
3/9/2023
Evelo Biosciences, Inc. (Nasdaq: EVLO), today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights.
-
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
3/1/2023
Evelo Biosciences, Inc. announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET.
-
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
2/27/2023
Evelo Biosciences, Inc. today announced that its first extracellular vesicle (EV) product candidate, EDP2939, has progressed to dosing in a Phase 2 psoriasis clinical trial after completing a safety and tolerability review from a first cohort of human volunteers.
-
Evelo Biosciences Provides Clinical and Business Updates
2/1/2023
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.
-
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
12/16/2022
Evelo Biosciences, Inc. today announced it has entered into a senior secured loan agreement with Horizon Technology Finance Corporation (Horizon) (Nasdaq: HRZN).
-
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
11/15/2022
Evelo Biosciences, Inc. (Nasdaq:EVLO) today announced the publication of a peer-reviewed article explaining the scientific basis of the Small Intestinal Axis1 and that it will hold a Science Symposium on Wednesday, November 30th, including discussion of how this science enables the broad inflammation resolving potential of SINTAX medicines.
-
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
11/14/2022
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced its third quarter 2022 financial results and business highlights.
-
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
11/8/2022
Evelo Biosciences, Inc. announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 7:25 a.m. GMT.
-
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
9/7/2022
Evelo Biosciences, Inc. presented biomarker data demonstrating the broad anti-inflammatory effects of EDP1815, the Company’s lead product candidate in inflammation, in a Phase 2 clinical trial in psoriasis.
-
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
9/1/2022
Evelo Biosciences, Inc. announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Health Care Conference on Tuesday, September 13th, 2022 at 12:20 p.m. ET.
-
Evelo Biosciences Announces Grant of Inducement Award - Sep 01, 2022
9/1/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, announced that on September 1, 2022, Marella Thorell commenced her services as Evelo’s Chief Financial Officer.
-
This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.
-
Evelo Biosciences Announces Succession Plan
8/11/2022
Evelo Biosciences, Inc. announced the succession plan for Simba Gill, Ph.D., to transition from his roles as Chief Executive Officer and President to the role of Chair of the Board of Directors and return to Flagship Pioneering to help launch, grow, and guide bioplatform companies.
-
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
8/11/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, reported financial results and business highlights for the second quarter 2022.
-
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
8/5/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, announced that it will host a conference call and live webcast at 7:30 a.m. ET on Thursday, August 11, 2022, to report its second quarter 2022 financial results.
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers.
-
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
7/18/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, announced the appointment of Marella Thorell as Chief Financial Officer, effective September 1, 2022.
-
Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock
5/25/2022
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 54,246,358 shares of common stock (the “Shares”) at a purchase price of $1.46 per share, resulting in gross proceeds of $79.2 million.
-
Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
5/12/2022
Evelo Biosciences, Inc. reported financial results and business highlights for the first quarter 2022.